Integrating Discovery, Improving Efficiency

RTX-002 is a targeted anti-PD-1 monoclonal antibody that binds PD-1 without blocking PD-L1 or PD-L2 binding.  RTX-002 agonizes PD-1 on T cells resulting in suppression of T cell proliferation, activation, and effector functions.  T Cell activation is required to drive autoantibody production and peripheral cytokine release in autoimmune diseases.  Therefore, allosteric or direct agonism of the PD-1 receptor promises to suppress T Cell activity and reduce autoimmunity in patients afflicted with serious autoimmune diseases.

RTX-003 is a targeted anti-CD25 monoclonal antibody that binds CD25 without blocking IL-2 on the high-affinity IL-2 receptor alpha on T regulatory (T reg) cells.   Increased T regulatory cells and/or decreased active T cells in a tumor correlate with lower Overall Survival (OS) and Progression-Free Survival (PFS) in a variety of tumor types.  RTX-003 is designed to induce T reg cell death, eliminating the suppressing influence Treg cells impose, thus supporting tumor immunity.